1-chloro-2-fluorobenzene

We are 1-chloro-2-fluorobenzene CAS:348-51-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  1-chloro-2-fluorobenzene
CAS.NO:348-51-6
Synonyms: o-Chlorofluorobenzene;
2-Chlorofluorobenzene;
o-Fluorochlorobenzene;
chlorofluorobenzene;
1,2-chlorofluorobenzene;
Molecular Formula:C6H4ClF
Molecular Weight: 130.54700
 
Physical and Chemical Properties:
Density: 1.244 g/mL at 25 °C(lit.)
Melting point:  −43-−42 °C(lit.)
Boiling point: 137-138 °C(lit.)
Flash point: 88 °F
Index of Refraction:1.501
 
Specification:
Appearance: Colorless to light brown transparent liquid
Purity:≥99.0%
 
Packing:25kg/drum
Storage:Storage conditions:2-8ºC.Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application:   Applications for organic intermediates

 1-chloro-2-fluorobenzene


Related News: At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.Sulfato de 4-aminofenol CAS:63084-98-0 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.3-Bromo-2-fluorobenzoic acid As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.N-etiletilendiamina CAS:110-72-5 As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.

Related Products
Product Name
(2-chloro-4-fluorophenyl)methanol View Details
Palmitoyl Tripeptide-38 View Details
N,N’-Bis(acetoacetyl)-o-toluidine View Details
2-Fluoro-4-(methoxycarbonyl)phenylboronic acid manufacturer Phthalimide manufacturer Bis[1,3-bis( 2-ethenyl)-1,1,3,3-tetramethyldisiloxane]platinum manufacturer 5-Bromo-2-fluorotoluene manufacturer 2,3-Pyrazinedicarboxylic Acid manufacturer